Reginald Seeto - Jun 9, 2021 Form 4 Insider Report for CareDx, Inc. (CDNA)

Role
President and Chief Executive Officer, Director
Signature
/s/ Reginald Seeto
Stock symbol
CDNA
Transactions as of
Jun 9, 2021
Transactions value $
-$1,060,753
Form type
4
Date filed
6/11/2021, 05:51 PM
Previous filing
Jun 9, 2021
Next filing
Jun 25, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDNA Common Stock Options Exercise $169K +6.09K +4.27% $27.72 149K Jun 9, 2021 Direct F1
transaction CDNA Common Stock Options Exercise $158K +5.83K +3.92% $27.17 155K Jun 9, 2021 Direct F1
transaction CDNA Common Stock Options Exercise $117K +4.79K +3.1% $24.35 159K Jun 9, 2021 Direct F1
transaction CDNA Common Stock Sale -$1.5M -16.7K -10.49% $90.01 143K Jun 9, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDNA Employee Stock Option (right to buy) Options Exercise $0 -6.09K -6.81% $0.00 83.4K Jun 9, 2021 Common Stock 6.09K $27.72 Direct F1, F3
transaction CDNA Employee Stock Option (right to buy) Options Exercise $0 -5.83K -18.23% $0.00 26.2K Jun 9, 2021 Common Stock 5.83K $27.17 Direct F1, F4
transaction CDNA Employee Stock Option (right to buy) Options Exercise $0 -4.79K -11.98% $0.00 35.2K Jun 9, 2021 Common Stock 4.79K $24.35 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.15, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
F3 25% of the shares subject to the option vested on November 26, 2019 and 1/48th of the shares subject to the option vest monthly thereafter.
F4 1/4th of the shares subject to the option vested on February 4, 2019 and 1/48th of the shares subject to the option vest monthly thereafter.
F5 1/4th of the shares subject to the option vested on January 29, 2021 and 1/48th of the shares subject to the option vest monthly thereafter.

Remarks:

President and Chief Executive Officer